As a novel and testable hypothesis, we propose defining a “functional cut-off” for pyroptosis components based on gasdermin expression (GSDME/GSDMD), cytokine profiles, and the magnitude of cell death (sublytic vs. lytic), along with cancer stage and cellular type to predict whether pyroptosis elicits anti-tumor or immunosuppressive effects in a given tumor. The gene discussed is GSDMD; the disease is neoplasm.